<DOC>
	<DOC>NCT00502567</DOC>
	<brief_summary>A multicentre, 2-part study to assess the safety and tolerability of once daily oral doses of AZD2171 when administered with various anticancer regimens (part A) and to confirm the tolerability of its combination with FOLFOX (part B).</brief_summary>
	<brief_title>A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>histologically confirmed metastatic cancer that is not amenable to surgery or radiation therapy with curative intent measurable lesion by CT or other techniques according to RECIST Inadequate bone marrow reserve history of poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>advanced solid tumors</keyword>
	<keyword>AZD2171</keyword>
	<keyword>Phase I</keyword>
</DOC>